TVWM
RVLP

Tower View Wealth Management’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Tower View Wealth Management’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,100
Closed -$5K – 196
2023
Q1 		$5K Hold
4,100
– – ﹤0.01% 134
2022
Q4 		$5K Hold
4,100
– – ﹤0.01% 141
2022
Q3 		$9K Hold
4,100
– – 0.01% 122
2022
Q2 		$6K Hold
4,100
– – ﹤0.01% 136
2022
Q1 		$7K Buy
+4,100
New +$5.86K ﹤0.01% 157

Other funds holding RVLP

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
RA
Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tower View Wealth Management's RVLP Position: Q2 2023 in Review

Tower View Wealth Management sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q2 2023, closing a stake of 4,100 shares — an estimated $5K sold.

Tower View Wealth Management first reported a position in RVLP in Q1 2022 and held it in 5 quarters. The position peaked at $9K in Q3 2022. 36 funds tracked by Wall St. Rank hold RVLP as of Q2 2023.

  • Tower View Wealth Management reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Tower View Wealth Management sold 4,100 RVL Pharmaceuticals plc Ordinary Shares shares in Q2 2023, an estimated $5K.
  • Tower View Wealth Management first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q1 2022 and held it in 5 quarters.
  • Tower View Wealth Management's RVL Pharmaceuticals plc Ordinary Shares position peaked at $9K in Q3 2022.
  • 36 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q2 2023.

Based on Tower View Wealth Management's 13F filing for Q2 2023, filed 31 Jul 2023.